NASDAQ:EXEL - Exelixis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $17.82 +0.17 (+0.96 %) (As of 12/13/2019 04:00 PM ET) Add Compare Today's Range$17.68Now: $17.82▼$18.3250-Day Range$15.21MA: $16.61▼$17.8252-Week Range$15.02Now: $17.82▼$25.31Volume3.08 million shsAverage Volume3.07 million shsMarket Capitalization$5.41 billionP/E Ratio12.46Dividend YieldN/ABeta1.78 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Commercial physical research Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:EXEL Previous Symbol CUSIP30161Q10 CIK939767 Webhttp://www.exelixis.com/ Phone650-837-7000Debt Debt-to-Equity Ratio0.01 Current Ratio6.89 Quick Ratio6.80Price-To-Earnings Trailing P/E Ratio12.46 Forward P/E Ratio18.37 P/E Growth2.32 Sales & Book Value Annual Sales$853.83 million Price / Sales6.34 Cash Flow$1.54 per share Price / Cash Flow11.60 Book Value$4.31 per share Price / Book4.13Profitability EPS (Most Recent Fiscal Year)$1.43 Net Income$690.07 million Net Margins64.05% Return on Equity25.55% Return on Assets23.04%Miscellaneous Employees484 Outstanding Shares303,846,000Market Cap$5.41 billion Next Earnings Date2/11/2020 (Estimated) OptionableOptionable Receive EXEL News and Ratings via Email Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EXEL Rates by TradingView Exelixis (NASDAQ:EXEL) Frequently Asked Questions What is Exelixis' stock symbol? Exelixis trades on the NASDAQ under the ticker symbol "EXEL." How were Exelixis' earnings last quarter? Exelixis, Inc. (NASDAQ:EXEL) posted its earnings results on Wednesday, October, 30th. The biotechnology company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.12. The biotechnology company earned $271.70 million during the quarter, compared to the consensus estimate of $228.17 million. Exelixis had a net margin of 64.05% and a return on equity of 25.55%. The firm's revenue was up 20.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.44 EPS. View Exelixis' Earnings History. When is Exelixis' next earnings date? Exelixis is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Exelixis. What price target have analysts set for EXEL? 9 brokers have issued twelve-month target prices for Exelixis' stock. Their forecasts range from $19.00 to $35.00. On average, they anticipate Exelixis' stock price to reach $26.11 in the next year. This suggests a possible upside of 46.5% from the stock's current price. View Analyst Price Targets for Exelixis. What is the consensus analysts' recommendation for Exelixis? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis. Has Exelixis been receiving favorable news coverage? Media coverage about EXEL stock has been trending neutral this week, InfoTrie reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Exelixis earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Exelixis. Are investors shorting Exelixis? Exelixis saw a decline in short interest in November. As of November 15th, there was short interest totalling 15,690,000 shares, a decline of 5.0% from the October 31st total of 16,520,000 shares. Based on an average trading volume of 2,790,000 shares, the short-interest ratio is presently 5.6 days. Approximately 5.3% of the company's shares are sold short. View Exelixis' Current Options Chain. Who are some of Exelixis' key competitors? Some companies that are related to Exelixis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Repligen (RGEN). What other stocks do shareholders of Exelixis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), BioMarin Pharmaceutical (BMRN), Gilead Sciences (gild), Incyte (INCY), Intel (INTC), Celgene (CELG) and Corbus Pharmaceuticals (CRBP). Who are Exelixis' key executives? Exelixis' management team includes the folowing people: Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50) Who are Exelixis' major shareholders? Exelixis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include State Street Corp (3.44%), First Trust Advisors LP (1.32%), Pictet Asset Management Ltd. (1.00%), Stephens Investment Management Group LLC (0.29%), Chicago Capital LLC (0.26%) and Rhumbline Advisers (0.25%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis. Which institutional investors are selling Exelixis stock? EXEL stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Millennium Management LLC, Rhenman & Partners Asset Management AB, SG Americas Securities LLC, Great West Life Assurance Co. Can, Capital Management Corp VA, Stifel Financial Corp and Tower Research Capital LLC TRC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis. Which institutional investors are buying Exelixis stock? EXEL stock was bought by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., Great Point Partners LLC, State Street Corp, Man Group plc, State of New Jersey Common Pension Fund D, Mackay Shields LLC, California Public Employees Retirement System and Squarepoint Ops LLC. View Insider Buying and Selling for Exelixis. How do I buy shares of Exelixis? Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Exelixis' stock price today? One share of EXEL stock can currently be purchased for approximately $17.82. How big of a company is Exelixis? Exelixis has a market capitalization of $5.41 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis. What is Exelixis' official website? The official website for Exelixis is http://www.exelixis.com/. How can I contact Exelixis? Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected] MarketBeat Community Rating for Exelixis (NASDAQ EXEL)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 439 (Vote Outperform)Underperform Votes: 396 (Vote Underperform)Total Votes: 835MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/13/2019 by MarketBeat.com StaffFeatured Article: What are Institutional Investors?